(CIDRAP News) If someone tried to kill Americans with Bacillus anthracis spores today, the nation would have a better medical tool chest for treating the sick and those potentially exposed than it had 10 years ago, when the anthrax letter attacks killed five people, but anthrax defenses are still a work in progress.
(CIDRAP News) The price-tag for federal investments in new flu vaccine technology has been difficult to get a handle on, but yesterday in a review for Congress the Government Accountability Office (GAO) put the number at $2.1 billion since fiscal year 2005.
(CIDRAP News) – Iomai Corp., a biotechnology company that specializes in needle-free vaccines, announced today that it will receive a grant from the US Department of Defense (DoD) to fund preclinical development of a patch-based anthrax vaccine.
The 1-year grant to Iomai, based in Gaithersburg, Md., will be in the form of a $943,856 cost reimbursement from the US Army Medical Research and Material Command, according to a press release from Iomai.
(CIDRAP News) The US government's attempt to add a next-generation anthrax vaccine to its stockpile failed because of a premature contract award, unrealistic expectations, and confusion about how the vaccine would be used, according to the Government Accountability Office (GAO), the investigative agency of Congress.